Compare Stocks → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALRNOTCMKTS:ASPCFNASDAQ:IMRNNASDAQ:MYOS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALRNAileron Therapeutics$4.93+3.8%$5.40$1.01▼$7.42$83.66M2.2264,570 shs102,247 shsASPCFAcerus Pharmaceuticals$0.22$0.22$0.22▼$8.16$1.70M0.691,500 shsN/AIMRNImmuron$2.58+4.9%$5.04$1.92▼$28.99$14.71M1.4323,679 shs1,273 shsMYOSMYOS RENS Technology$3.35$0.74▼$3.85$16.70M1.081.68 million shsN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALRNAileron Therapeutics0.00%-11.21%-23.39%+3.04%+227.63%ASPCFAcerus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%IMRNImmuron-2.69%+5.42%-1.56%+36.39%+17.67%MYOSMYOS RENS Technology0.00%0.00%0.00%-50.18%+389.29%Global crypto currency reset (41 major banks signed up) (Ad)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALRNAileron Therapeutics1.8942 of 5 stars3.53.00.00.02.41.70.0ASPCFAcerus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AIMRNImmuronN/AN/AN/AN/AN/AN/AN/AN/AMYOSMYOS RENS TechnologyN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALRNAileron Therapeutics3.00Buy$19.00285.40% UpsideASPCFAcerus PharmaceuticalsN/AN/AN/AN/AIMRNImmuronN/AN/AN/AN/AMYOSMYOS RENS TechnologyN/AN/AN/AN/ACurrent Analyst RatingsLatest MYOS, ALRN, IMRN, and ASPCF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024ALRNAileron TherapeuticsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $19.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALRNAileron TherapeuticsN/AN/AN/AN/A$1.41 per shareN/AASPCFAcerus Pharmaceuticals$2.12M0.80N/AN/A($3.38) per share-0.07IMRNImmuron$1.22M12.05N/AN/A$2.32 per share1.11MYOSMYOS RENS Technology$1.03M0.00N/AN/A$0.13 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALRNAileron Therapeutics-$15.73M-$3.38N/AN/AN/AN/A-130.32%-39.23%5/13/2024 (Estimated)ASPCFAcerus Pharmaceuticals-$33.82M-$3.57N/A∞N/A-924.33%N/A-74.62%N/AIMRNImmuron-$2.55MN/A0.00∞N/AN/AN/AN/AN/AMYOSMYOS RENS Technology-$4.26MN/AN/AN/AN/A-277.82%-166.68%-104.95%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALRNAileron TherapeuticsN/AN/AN/AN/AN/AASPCFAcerus PharmaceuticalsN/AN/AN/AN/AN/AIMRNImmuronN/AN/AN/AN/AN/AMYOSMYOS RENS TechnologyN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALRNAileron TherapeuticsN/A4.174.17ASPCFAcerus PharmaceuticalsN/A0.670.34IMRNImmuronN/A8.527.79MYOSMYOS RENS Technology0.113.781.94OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALRNAileron Therapeutics90.89%ASPCFAcerus PharmaceuticalsN/AIMRNImmuron0.12%MYOSMYOS RENS Technology4.97%Insider OwnershipCompanyInsider OwnershipALRNAileron Therapeutics5.57%ASPCFAcerus PharmaceuticalsN/AIMRNImmuron7.01%MYOSMYOS RENS Technology45.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALRNAileron Therapeutics616.97 million16.03 millionNot OptionableASPCFAcerus Pharmaceuticals147.71 millionN/ANot OptionableIMRNImmuronN/A5.70 million5.30 millionNot OptionableMYOSMYOS RENS Technology1512.19 millionN/ANot OptionableMYOS, ALRN, IMRN, and ASPCF HeadlinesSourceHeadlineRen Zhengfei says US government 'underestimates' Huaweibbc.com - December 23 at 1:17 PMPioneer announces The Ren as Business Partner of the Yearrichlandsource.com - November 20 at 1:50 PMShenqiang Renbuffalo.edu - October 4 at 3:32 PMAnthony M. Newman to Lead REN-ISAC Cybersecurity Centercampustechnology.com - August 27 at 9:26 PMCarbon-based quantum technologysciencedaily.com - August 19 at 4:05 PMBio-active Peptides Market Size 2023-2031 Industrial Trends by Absolute Reports | with [93 Pages]marketwatch.com - May 11 at 1:13 AMLatest "Bio-active Peptides Market" Size Forecast 2023-2031: New Challenges, Drivers, and Restraintsmarketwatch.com - May 8 at 9:06 PMBio-active Peptides Market Size Dynamics 2023-2029marketwatch.com - April 13 at 3:09 PMRenQ Finance (RENQ) raises $5 million, makes some serious buzz with its all in one DeFi platformcointelegraph.com - April 6 at 1:03 PMGlobal Bio-active Peptides Market: Future Extrapolations and Emerging Updates for 2023-2027marketwatch.com - March 21 at 9:47 AMBio-active Protein Market Size 2023 Research Report by Industrial Growth Analysis and Forecast till 2027marketwatch.com - March 13 at 10:33 AMCan Huawei thrive despite American sanctions?economist.com - October 29 at 10:12 AMBio-active Peptides Market Size, Share, 2022 Global Trends, Development Status, Opportunities, Competitive Landscape and Growth by Forecast 2028marketwatch.com - September 28 at 9:57 AMBio-Active Protein Market Is Likely to Experience a Strong Growth During 2022-2028 with Top Countries Datamarketwatch.com - August 4 at 1:49 AMRenaissance Festival tickets go on sale Friday, Aug. 5independenttribune.com - August 1 at 9:38 AMRensair raises $7m to establish clean air as a human rightwfmz.com - May 10 at 9:43 AMBioactive Protein Market Latest Analysis Report 2022: Global Industry Size, Share, Production, Growth Drivers and Strategic Outlook 2026wicz.com - January 12 at 2:06 PMBioactive Peptide Market to See Booming Growth 2021-2028 | Archer Daniels Midland Company, Seagarden AS, Phermpep Co. Ltd., Arlak Biotech Pvt. Ltd.chipdesignmag.com - November 1 at 10:13 PMICYMI: Everything you need to know about the iPhone 13yahoo.com - September 26 at 10:38 PMMYOS RENS Technology Inc. Common Stock (MYOS)nasdaq.com - July 29 at 10:47 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAileron TherapeuticsNASDAQ:ALRNAileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.Acerus PharmaceuticalsOTCMKTS:ASPCFAcerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.ImmuronNASDAQ:IMRNImmuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.MYOS RENS TechnologyNASDAQ:MYOSMedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.